Review: Phytocannabinoids Could Target Kidney Glucose Transporters for Diabetes Management

In silico studies show high-affinity binding of phytocannabinoids to SGLT2 substrate pocket. CBG and THCV modulate SGLT2-related pathways via TRP channels and CB receptors. In vivo, THCV and CBD demonstrate glucose-lowering, insulin-sensitizing, weight-reducing, and organ-protective effects. Pilot data (n=62): THCV decreased fasting glucose, enhanced beta-cell function, no psychoactive side effects.

Narrative review covering molecular docking, in vitro receptor binding/transport assays, in vivo rodent models, pilot clinical studies, and comparison with synthetic SGLT2 inhibitors (empagliflozin, dapagliflozin, etc.).

SGLT2 inhibitors have transformed diabetes care but have side effects (urinary infections, ketoacidosis). If phytocannabinoids can modulate the same pathway with fewer side effects and additional metabolic benefits, they could complement or offer alternatives to current treatments.

The pleiotropic effects of phytocannabinoids — glucose lowering, insulin sensitization, weight reduction, anti-inflammation, organ protection — position them uniquely as multi-target diabetes agents, in contrast to the single-mechanism approach of synthetic SGLT2 inhibitors.

Direct SGLT2 IC50 values for phytocannabinoids not yet determined. Low oral bioavailability is a major hurdle. Pilot clinical data is very preliminary (n=62). Polypharmacology may lead to off-target effects. No large-scale clinical trials.